ConjuChem

Peptide conjugate therapeutics

Privately held: no public share price · Canada

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
GLP-1 receptorPeptide
Type 2 Diabetes

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

November 2024Filing acceptedCJC-1134-PCNMPA accepts the albenatide (CJC-1134-PC) marketing application in type 2 diabetes
CN, NMPA · Hebei Changshan Biochemical Pharmaceutical Co., Ltd · Source ↗

Financial reports

No financial reports recorded.